IN2012DN02304A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02304A IN2012DN02304A IN2304DEN2012A IN2012DN02304A IN 2012DN02304 A IN2012DN02304 A IN 2012DN02304A IN 2304DEN2012 A IN2304DEN2012 A IN 2304DEN2012A IN 2012DN02304 A IN2012DN02304 A IN 2012DN02304A
- Authority
- IN
- India
- Prior art keywords
- aging
- arnox
- disorders
- recombinant
- nadh oxidase
- Prior art date
Links
- 102000001708 Protein Isoforms Human genes 0.000 abstract 3
- 108010029485 Protein Isoforms Proteins 0.000 abstract 3
- 108010007843 NADH oxidase Proteins 0.000 abstract 2
- 230000032683 aging Effects 0.000 abstract 2
- 230000002431 foraging effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003298 DNA probe Substances 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000018109 developmental process Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23436809P | 2009-08-17 | 2009-08-17 | |
| PCT/US2010/045745 WO2011022387A1 (en) | 2009-08-17 | 2010-08-17 | Cloning and expression of arnox protein transmembrane 9 superfamily (tm9sf), methods and utility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02304A true IN2012DN02304A (enExample) | 2015-08-21 |
Family
ID=43607300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2304DEN2012 IN2012DN02304A (enExample) | 2009-08-17 | 2010-08-17 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120315629A1 (enExample) |
| EP (1) | EP2467392A4 (enExample) |
| JP (1) | JP2013502217A (enExample) |
| CN (1) | CN102574889A (enExample) |
| CA (1) | CA2771277A1 (enExample) |
| IN (1) | IN2012DN02304A (enExample) |
| WO (1) | WO2011022387A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8465939B2 (en) | 2010-03-02 | 2013-06-18 | Nox Technologies, Inc. | Aging-related circulating particle-associated lipoprotein B oxidase (apoBNOX) and inhibitors thereof |
| WO2014209280A1 (en) * | 2013-06-25 | 2014-12-31 | Mor-Nutech, Inc. | Growth-related enox proteins from plants with yield enhancement potential, sequences and methods |
| CN114774418B (zh) * | 2022-04-19 | 2023-11-14 | 深圳市人民医院 | shRNA分子及其在敲低TM9SF2基因表达中的应用 |
| CN115772574A (zh) * | 2022-10-27 | 2023-03-10 | 华南农业大学 | 鸡tm9sf2基因鉴定方法及其膜外结构域的原核表达 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030175787A1 (en) * | 1997-10-28 | 2003-09-18 | Incyte Corporation | Vesicle membrane proteins |
| US20070203083A1 (en) * | 2003-06-13 | 2007-08-30 | Mootha Vamsi K | Methods Of Regulating Metabolism And Mitochondrial Function |
| US7473531B1 (en) * | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US8014957B2 (en) * | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| RU2518340C2 (ru) * | 2007-03-30 | 2014-06-10 | Эббви Инк | Элементы рекомбинантного вектора экспрессии (reves) для усиления экспрессии рекомбинантных белков в клетках-хозяевах |
| US8097407B2 (en) * | 2008-01-25 | 2012-01-17 | Hansabiomed Ou | Metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression |
-
2010
- 2010-08-17 WO PCT/US2010/045745 patent/WO2011022387A1/en not_active Ceased
- 2010-08-17 CN CN2010800366427A patent/CN102574889A/zh active Pending
- 2010-08-17 IN IN2304DEN2012 patent/IN2012DN02304A/en unknown
- 2010-08-17 EP EP10810479.5A patent/EP2467392A4/en not_active Withdrawn
- 2010-08-17 CA CA2771277A patent/CA2771277A1/en not_active Abandoned
- 2010-08-17 JP JP2012525639A patent/JP2013502217A/ja not_active Withdrawn
- 2010-08-17 US US13/390,795 patent/US20120315629A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN102574889A (zh) | 2012-07-11 |
| CA2771277A1 (en) | 2011-02-24 |
| EP2467392A4 (en) | 2013-06-19 |
| US20120315629A1 (en) | 2012-12-13 |
| WO2011022387A1 (en) | 2011-02-24 |
| EP2467392A1 (en) | 2012-06-27 |
| JP2013502217A (ja) | 2013-01-24 |
| WO2011022387A8 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092522L (no) | Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA | |
| CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
| AU2008298744A8 (en) | MiRNA expression in human peripheral blood microvesicles and uses thereof | |
| BRPI0811210A2 (pt) | Agente de formação de imagem, composição farmacêutica, métodos de preparação de um agente de formação de imagem, de formação de imagem óptica in vivo do corpo de um mamífero e de detecção, avaliação do estágio, diagnóstico, monitoração da progressão da doença ou monitoração do tratamento de câncer colorretal do corpo de um mamífero, e, kit para a preparação da composição farmacêutica. | |
| WO2008108803A3 (en) | Immune cell biosensors and methods of using same | |
| WO2008103645A3 (en) | Prostate cancer and melanoma antigens | |
| MX342791B (es) | Ensayo elisa para la detección de vegf. | |
| EP2068929A4 (en) | METHOD OF DETECTING AND TREATING SKIN DISORDERS | |
| MX2013003929A (es) | Biomarcadores de citoquina como marcadores predictivos de respuesta clinica para acetato de glatiramer. | |
| WO2011156734A3 (en) | Method of characterizing vascular diseases | |
| MX2010004251A (es) | Anticuerpo anti-bst2. | |
| WO2005040421A3 (en) | Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues | |
| IN2012DN02304A (enExample) | ||
| NZ609567A (en) | Markers of endothelial progenitor cells and uses thereof | |
| ES3005161T3 (en) | Diagnostic method of a skin showing signs of aging | |
| MX2009001070A (es) | Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. | |
| RU2013104137A (ru) | Изоформы bard1 при раке легкого и колоректальном раке и их применение | |
| CN104603616B (zh) | 使用纤蛋白‑3和/或肌聚糖γ作为指标评价脂肪团的方法和评价脂肪团有效药物的方法 | |
| WO2014117680A3 (zh) | 外周血细胞TRPC6mRNA水平用于早期预测/诊断老年性痴呆 | |
| EP2539709A4 (en) | MORBUS ALZHEIMER SPECIFIC CHANGES OF PROTEIN KINASE C EPSILON (PKC EPSILON) PROTEIN MIRRORS | |
| MY148542A (en) | A method for the assessment of cancer in a biological sample obtained from a subject | |
| WO2011141153A8 (en) | Methods for the diagnosis and prognosis of a tumor using bcat1 protein | |
| WO2012144755A3 (ko) | 리포칼린 2 발현 수준을 측정하는 경도 인지 장애 진단용 조성물, 키트 및 경도인지 장애 진단을 위한 정보 제공방법 | |
| ATE500275T1 (de) | Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten | |
| WO2009069007A3 (en) | Composition and method for prediction of complicated disease course in crohn's disease |